Skip to content
Tezacitabine
Tezacitabine is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
49 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PneumoniaD011014EFO_0003106J1812237
AppendicitisD001064EFO_0007149K37224
Intraabdominal infectionsD0594131123
NephrolithiasisD053040N20.0112
Urinary tract infectionsD014552EFO_0003103N39.0112
Necrotizing enterocolitisD020345EFO_0003928K55.3112
CholelithiasisD002769EFO_0004799K8022
Neonatal sepsisD000071074HP_00401871112
Wound infectionD01494611
Open fracturesD00559711
Show 5 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InfectionsD007239EFO_00005441113
SepsisD018805A41.91113
Hiv infectionsD015658EFO_0000764B201213
ChorioamnionitisD002821O41.122213
Lung abscessD008169EFO_1001362J85.2112
Kidney calculiD007669EFO_0004253N20.011
Aspiration pneumoniaD011015EFO_1001399J69.011
MeningitisD008581EFO_0000584G03111
Bacterial pneumoniaD018410EFO_1001272J15.911
Child nutrition disordersD015362111
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cleft palateD002972Q3511
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Jaw fracturesD00757211
DystoniaD004421HP_0001332G2411
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Salmonella infectionsD012480EFO_1001418A02.911
EndometritisD004716EFO_100131211
Premature birthD047928EFO_0003917O6011
PeritonitisD010538EFO_0008588K6511
Listeria monocytogenesD008089NCBITaxon_163911
Gastrointestinal diseasesD00576711
ColicD003085HP_0011848R10.8311
Premature obstetric laborD007752O6011
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTEZACITABINE
INNtezacitabine
Description
Tezacitabine is a ribonucleotide reductase inhibitor. It is a synthetic purine nucleoside analogue with potential antineoplastic activity. It is used in synthetic DNA.
Classification
Small molecule
Drug classnucleoside antiviral or antineoplastic agents, cytarabine or azarabine derivatives
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)/C2=C\F)c(=O)n1.O
Identifiers
PDB
CAS-ID130306-02-4
RxCUI
ChEMBL IDCHEMBL3989496
ChEBI ID
PubChem CID6435808
DrugBank
UNII ID7607Y95N9S (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 13 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
5,180 adverse events reported
View more details